OTIC Otonomy Inc.

2.23
+0.04  (+2%)
Previous Close 2.19
Open 2.18
Price To Book 1.16
Market Cap 68,568,952
Shares 30,748,409
Volume 9,720
Short Ratio
Av. Daily Volume 32,106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 3Q 2019 with data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial initiation announced April 11, 2019 with data due 1H 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT
  2. Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  3. Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
  4. Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider
  5. Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
  6. Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
  7. Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
  8. Otonomy: 1Q Earnings Snapshot
  9. Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
  10. Otonomy, Inc. to Host Earnings Call
  11. Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
  12. Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
  13. Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
  14. Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
  15. Do Institutions Own Otonomy, Inc. (NASDAQ:OTIC) Shares?
  16. Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
  17. The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
  18. Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
  19. Will Otonomy Continue to Surge Higher?
  20. Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT